Glycine Before Bed: What the Small Sleep Trials Found

A glycine powder labeled for bedtime can sound appealing when falling asleep takes longer than you want. Before buying it, check which outcome supports the claim. Getting to sleep sooner, spending more of the night in deep sleep and feeling less tired tomorrow require separate measurements.

The sleep recordings came from 11 people

The 2007 trial¹ enrolled 11 volunteers, eight women and three men, aged 30–57. They reported poor sleep. In a randomized, single-blind crossover design, each received 3 grams of glycine and a flavored placebo in separate periods, within an hour of bedtime.¹

Hospital sleep recordings covered two consecutive nights per condition. The first was discarded as acclimatization, leaving one analyzed night per condition. Glycine shortened the time to stage 2 sleep and to the first stage 3, or slow-wave, sleep. Reported sleep satisfaction also improved.¹

Sleep-stage proportions did not change. Reaching slow-wave sleep sooner does not establish that more of the night was spent there. This distinction matters when a product promises “more deep sleep.”¹

The shortened-night experiment analyzed seven men

The 2012 trial² recruited ten healthy men without sleep disorders; withdrawal and medication-related exclusions left seven men for analysis. All participants worked at Ajinomoto, and three authors listed company affiliations.²

Each man received glycine and placebo in separate periods. For three nights per period, time in bed was cut by 25%, averaging 5.5 hours instead of 7.3. The glycine dose was 3 grams, 30 minutes before bed. Sleep logs monitored the nights; this experiment did not record sleep stages.²

Fatigue ratings improved significantly on day 1, but not day 3. Day-1 sleepiness ratings did not reach significance. A computerized vigilance task showed faster reaction times on both assessed days.²

Those mixed findings cannot establish that glycine compensates for insufficient sleep. The study tested brief, imposed sleep restriction in healthy men, rather than treatment of chronic insomnia.²

A review of 52 studies was not 52 sleep trials

A systematic review published in 2023 covered 52 studies across many physiological systems, including psychiatric and metabolic conditions. Its discussion of sleep benefits in healthy people described bedtime interventions lasting only two to four days.³

The reviewers warned that the sleep, fatigue and alertness evidence came from small samples with an overall high risk of bias. A broad review’s total study count should not be used as the number of experiments supporting a bedtime product.³

What to ask before spending money

Bring the label and the claim to your appointment or pharmacy conversation. Three useful questions are:

• Does the evidence concern the symptom I want to change: falling asleep, staying asleep or daytime tiredness?
• Does this product provide glycine alone, or a mixture whose ingredients were never tested together in these experiments?
• What would count as a worthwhile change, and when would we reassess persistent symptoms?

The studied 3-gram amount describes the experiments. It does not establish the best dose, a benefit from increasing it or the safety of months of nightly use. The short trials above cannot answer those questions.¹²

For long-term insomnia, the National Heart⁴, Lung, and Blood Institute says cognitive behavioral therapy for insomnia, CBT-I, is usually the first treatment recommended. It generally runs six to eight weeks and can be delivered in person, by telephone or online. Discuss supplements with your healthcare provider as part of that treatment conversation.⁴

Our guide to insomnia and CBT-I explains the treatment in more detail. Chapter 10 of Did I Do That in My Sleep? covers being in bed all night yet tired all day, including what CBT-I addresses and how to seek access.